PeptidePros
All Peptides

TB-500

Also known as: Thymosin Beta-4 fragment, LKKTETQ

Evidence Tier Cmed-high riskintermediatenot approved

Marketed thymosin beta-4 fragment (LKKTETQ actin-binding motif) studied for soft-tissue repair in preclinical models.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Sequence Ambiguity

Significant sequence ambiguity exists for this product in the market. Vendors must specify exact peptide sequence, and products should not be assumed interchangeable with related full-length peptides or fragments.

Overview

TB-500 is often marketed as a thymosin beta-4-derived fragment, specifically the LKKTETQ actin-binding motif (residues 17-23). Clinical evidence for TB-500 per se is limited compared to full-length thymosin beta-4. Sequence ambiguity between TB-500 and full Tβ4 is a material concern — vendors must specify exact sequence. WADA classifies thymosin-β4 derivatives under growth factor modulators.

Research Details

Mechanism of Action

Actin-binding domain effects (cell migration and angiogenesis signatures) proposed; clinical evidence limited.

Study Dose Range

Human evidence for TB-500 specifically is limited; thymosin beta-4 clinical work is more substantial.

Administration Routes

subcutaneous

Onset / Timeline

Preclinical: varies by injury model. Consumer timelines are speculative.

Expected Effects

Soft-tissue repair and recovery signals in preclinical models.

Adverse Effects

Limited safety data; sequence ambiguity adds quality risk.

Contraindications

No established contraindications (insufficient data).

Interaction Notes

Unknown/insufficient. Caution when combining with full-length thymosin beta-4 due to sequence overlap.

Related Goals
Tissue Repair & Recovery
Known Interactions

caution with Thymosin Beta-4

TB-500 is often described as a thymosin beta-4 fragment/region; must confirm exact sequence and avoid mixing fragment vs full-length assumptions.

caution with BPC-157

Commonly marketed as a stack/blend in consumer market; clinical interaction evidence limited; treat as uncertain.

Available From

Amino Club

consumer RUO · COA: product page COA viewer

10 mg / 20 mg (variant-dependent) · from ~$49.99 to ~$89.99 (variant-dependent)

Consumer RUO; review product details carefully

A dedicated product page exists for this peptide, which makes it easier to review details before you buy.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Frequently Compared

BPC-157

Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.

Tier C

Thymosin Beta-4

Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.

Tier B-C

MGF E-domain

IGF-1 splice variant peptide studied preclinically for muscle repair signaling.

Tier C

GHK-Cu

Copper peptide complex with substantial topical/cosmetic literature for skin and hair repair.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.